All Issue

2020 Vol.1, Issue 3 Preview Page

Review article

June 2020. pp. 54-58
Abstract
References
1
Douketis JD et al., American College of Chest Physicians. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Throm- bosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, 2012
2
Vandvik PO et al., Spencer FA; American College of Chest Physicians. Pri- mary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, 2012
3
Assia EI et al., Effect of aspirin intake on bleeding during cataract surgery, J Cataract Refract Surg, 1998
10.1016/S0886-3350(98)80020-5
4
Burger W et al., Low-dose aspirin for secondary cardiovascular prevention: cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation: review and meta-analysis, J Intern Med, 2005
10.1111/j.1365-2796.2005.01477.x15836656
5
Herth FJ et al., Aspirin does not increase bleeding complications after transbronchial biopsy, Chest, 2002
10.1378/chest.122.4.146112377879
6
Khalifeh MR et al., The management of patients on anticoagulants prior to cutaneous surgery: case report of a thromboembolic complication, review of the literature, and evidence-based recommendations, Plast Reconstr Surg, 2006
10.1097/01.prs.0000221114.01290.8517016167
7
Grines CL et al., American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians, Prevention of premature dis-continuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians, J Am Dent Assoc, 2007
10.1161/CIRCULATIONAHA.106.18094417224480
8
Kushner FG et al., American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 2009
9
Holmes DR Jr et al., ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons, J Am Coll Cardiol, 2010
10
Bavry AA et al., Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials, Am J Med, 2006
10.1016/j.amjmed.2006.01.02317145250
11
Daemen J et al., Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study, Lancet, 2007
10.1016/S0140-6736(07)60314-6
12
Eisenstein EL et al., Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation, JAMA, 2007
10.1001/jama.297.16.1770-c
13
Roberts JR et al., Clinical procedures in emergency medicine, 4th ed. Philadelphia: W. B. Saunders; 2004
14
Fink MP, Textbook of critical care, 5th ed. Philadelphia: Else- vier Saunders; 2005
15
Gohlke-Barwolf C et al., Guidelines for prevention of thromboembolic events in val-vular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology, Eur Heart J, 1995
16
Eisen GM et al., American Society for Gastrointestinal Endoscopy. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures, Gastrointest Endosc, 2002
17
Douketis JD, Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians, Thromb Res, 2002
10.1016/S0049-3848(02)00387-0
18
Bonow RO et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 Focused update i corporated into the ACC/AHA 2006 guidelines for the mana-gement of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons, J Am Coll Cardiol, 2008
19
Jafri SM, Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy, Am Heart J, 2004
10.1016/j.ahj.2003.06.00114691412
20
Kearon C et al., Management of anticoagulation before and after elective surgery, N Engl J Med, 1997
10.1056/NEJM1997052233621079154771
21
Tiede DJ et al., Modern management of prosthetic valve anticoagulation, Mayo Clin Proc, 1998
10.4065/73.7.6659663198
22
Gage BF et al., Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin, Circulation, 2004
10.1161/01.CIR.0000145172.55640.9315477396
23
Pharmacology Weekly, Why is the low molecular weight he-parin, enoxaparin (Lovenox) dosed in mg while the other LMWH's (dalteparin (Fragmin) and tinzaparin (Innohep)) are dosed in IU/kg and is this difference clinically relevant? [Internet]. San Antonio: Pharmacology Weekly; 2014 [cited 2014 Apr 17]. Available from: http:// www.pharmacologyweekly.com/articles/lmwh- enoxaparin- lovenox-dalteparin-fragmin-dosing-differences.
24
Douketis JD et al., Bridging anticoagulation with low- molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery, Thromb Haemost, 2005
25
O'Donnell MJ et al., Brief communication: preoperative anticoagulant activity after bridging low-molecular- weight heparin for temporary interruption of warfarin, Ann Intern Med, 2007
10.7326/0003-4819-146-3-200702060-0000717283349
26
Landefeld CS et al., Anticoagulant-related bleeding: cli- nical epidemiology, prediction, and prevention, Am J Med, 1993
10.1016/0002-9343(93)90285-W
27
Spyropoulos AC et al., REGIMEN Investigators. Clinical outcomes with unfractionated heparin or low-molecular- weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry, J Thromb Haemost, 2006
10.1111/j.1538-7836.2006.01908.x16706967
Information
  • Publisher :The Association of Korean Urologists
  • Publisher(Ko) :대한비뇨의학과의사회
  • Journal Title :비뇨의학 Urology Digest
  • Volume : 1
  • No :3
  • Pages :54-58